Cargando…

Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis

Natalizumab is indicated as monotherapy for the treatment of relapsing-remitting multiple sclerosis; it prevents outbreaks and delays the progression of physical disability. Here, we report the case of a 30-year-old patient with multiple sclerosis receiving natalizumab as monotherapy who subsequentl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lima, Marina Rodrigues, Farias, Luís Arthur Brasil Gadelha, da Ponte, Maycon Fellipe, de Arruda Furtado, Luís Edmundo Teixeira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SMC Media Srl 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432828/ https://www.ncbi.nlm.nih.gov/pubmed/30931272 http://dx.doi.org/10.12890/2019_001046

Ejemplares similares

Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression
por: Persaud, Stephen P., et al.
Publicado: (2017)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Palpebral myiasis due Cochliomyia macellaria in an alcoholic patient
por: Farias, Luis Arthur Brasil Gadelha, et al.
Publicado: (2020)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

Meningitis due to Streptococcus suis in Two Patients with Occupational Exposure from Northeastern Brazil
por: Ponte de Matos, Francisco Breno, et al.
Publicado: (2021)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
por: Steinman, Lawrence
Publicado: (2012)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

Cognitive evolution in natalizumab-treated multiple sclerosis patients
por: Jacques, Francois H, et al.
Publicado: (2016)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
por: Ramos-Cejudo, Jaime, et al.
Publicado: (2011)

Septic Embolism in a Patient with Infective Endocarditis and COVID-19
por: Dias, Camila Negreiro, et al.
Publicado: (2020)

CANDIDEMIA ASSOCIADA À INFECÇÃO POR SARS‐COV‐2: UM RELATO DE DOIS CASOS
por: Farias, Luís Arthur Brasil Gadelha, et al.
Publicado: (2021)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab
por: Patti, Francesco, et al.
Publicado: (2009)

Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy
por: Gattringer, Thomas, et al.
Publicado: (2014)

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2012)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Disrupted balance of T cells under natalizumab treatment in multiple sclerosis
por: Kimura, Kimitoshi, et al.
Publicado: (2016)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
por: Maier, Smaranda, et al.
Publicado: (2020)

Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis
por: Kim, Ki Hoon, et al.
Publicado: (2021)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
por: Ganapathy Subramanian, Ranjani, et al.
Publicado: (2021)

Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis
por: Frisch, Esther S., et al.
Publicado: (2023)

Influence of natalizumab on resting-state connectivity in patients with multiple sclerosis
por: Corrêa, Diogo G., et al.
Publicado: (2023)

Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients
por: Yao, Karen, et al.
Publicado: (2008)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study
por: Fernández, O., et al.
Publicado: (2012)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jv6relvp8f0cvdd2298bob95sp